66th Annual Meeting of the Japanese Society of Neurology

Yuishin Izumi¹, Oren Levy², Ly Pham², Jutta Miller², Alexandre Sostelly³, Poulabi Banerjee², Zhentao Tong², Maria Rosario², Adnan Mahmood², Olivier Harari² (1.Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Japan, 2.Regeneron Pharmaceuticals, Inc., USA, 3.Alnylam Pharmaceuticals, USA)

Haruhisa Inoue¹, Keiko Imamura¹, Takashi Ayaki³, Makiko Nagai⁴, Kazutoshi Nishiyama⁴, Yasuhiro Watanabe⁵, Ritsuko Hanajima⁵, Hiroshi Kataoka⁶, Takao Kiriyama⁶, Hitoki Nanaura⁶, Kazuma Sugie⁶, Takehisa Hirayama⁷, Osamu Kano⁷, Masahiro Nakamori⁸, Hirofumi Maruyama⁸, Koji Fujita², Naoki Atsuta⁹, Gen Sobue¹⁰, Ryosuke Takahashi³, Yuishin Izumi² (1.Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan, 2.Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Japan, 3.Department of Neurology, Graduate School of Medicine, Kyoto University, Japan, 4.Department of Neurology, Kitasato University School of Medicine, Japan, 5.Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Japan, 6.Department of Neurology, Nara Medical University School of Medicine, Japan, 7.Department of Neurology, Toho University Faculty of Medicine, Japan, 8.Department of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan, 9.Department of Neurology, Aichi Medical University, Japan, 10.Aichi Medical University, Japan)

Daichi Imamura, Satoshi Hosoki, Kotaro Haruna, Ryosuke Oka, Kazuma Ota, Noriko Nomura, Satoru Fujiwara, Kota Maekawa, Junko Ishii, Nobuyuki Ohara, Hajime Yoshimura, Nobuo Kohara, Michi Kawamoto (Department of Neurology, Kobe City Medical Center General Hospital, Japan)

Satoru Morimoto¹, Chris Kato¹, Shinichi Takahashi^1,2, Shiho Nakamura¹, Fumiko Ozawa¹, Naoki Kobayashi¹, Daisuke Ito³, Yugaku Daté³, Kensuke Okada^1,3, Jin Nakahara³, Hideyuki Okano¹ (1.Keio University Regenerative Medicine Research Center, Japan, 2.Department of Neurology and Stroke Saitama Med Univ International Medical Center, Japan, 3.Department of Neurology, Keio University School of Medicine, Japan)

Koji Fujita¹, Tatsuo Itou², Yuumi Okuzono², Dnyaneshwar Warude², Miyakawa Shuuichi², Yoshimi Mihara¹, Naoko Matsui¹, Hiroyuki Morino³, Yusuke Kikukawa², Yuishin Izumi¹ (1.Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Japan, 2.Oncology Drug Discovery Unit Japan, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Japan, 3.Department of Medical Genetics, Tokushima University Graduate School of Biomedical Sciences, Japan)

Kentaro Sahashi¹, Toshio Saito², Hiroshi Takashima³, Fumiaki Tanaka⁴, Yachiyo Kuwatsuka⁵, Atsushi Hashizume⁶, Taihei Homma⁷, Hiromitsu Kawata⁸, Masahiko Ando⁵, Masahisa Katsuno^1,6 (1.Dept. of Neurology, Nagoya University, Japan, 2.Div. of Child Neurology, Dept. of Neurology, Osaka Toneyama Medical Center, Japan, 3.Dept. of Neurology and Geriatrics, Kagoshima University, Japan, 4.Dept. of Neurology and Stroke Medicine, Yokohama City University, Japan, 5.Dept. of Advanced Medicine, Nagoya University Hospital, Japan, 6.Dept. of Clinical Research Education, Nagoya University, Japan, 7.Medical, Biogen Japan, Japan, 8.Medical Affairs Division, Chugai Pharmaceutical, Japan)